Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emicerfont
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emicerfont is a small molecule, nonpeptide antagonist of the corticotropin-releasing factor type 1 (CRF1) receptor. It was developed by GlaxoSmithKline and acts by blocking the CRF1 receptor, thereby reducing adrenocorticotropic hormone (ACTH) release in response to stress. Emicerfont was investigated for the treatment of irritable bowel syndrome (IBS), anxiety disorders including social anxiety disorder, major depressive disorder, and alcoholism. Although it reached phase II clinical trials for these indications, development was discontinued due to insufficient efficacy for medical use. The drug continues to be used in research settings to study the role of CRF-ACTH signaling in stress-related disorders[1][2][3][4][5].
- Other names
- emicerfont [USAN:INN]786701-13-1UNII-OJ8EG4264PUNII-OJ-8EG4264PUNII-OJ 8EG4264P
02
Targets
CRHR1 (Corticotropin-releasing factor receptor 1)
Beyond the preview
Go deeper on emicerfont.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emicerfont.